Compare Crispr Therapeutics AG (CRSP) vs Tractor Supply Co (TSCO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Tractor Supply Co — how do they compare? Crispr Therapeutics AG trades at $50.54 (market cap $4.97B), while Tractor Supply Co trades at $31.13 (market cap $16.02B). The key difference: Tractor Supply Co is far larger — about 3.2× Crispr Therapeutics AG's market cap, and Tractor Supply Co pays a 3.14% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | TSCO | |
|---|---|---|
Market Cap | $4.97B | $16.02B |
Sector | Health | Consumer Cyclical |
52-Week High | $76.78 | $62.65 |
52-Week Low | $44.34 | $29.14 |
Enterprise Value | $3.32B | $22.21B |
Dividend Yield | — | 3.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
Tractor Supply (TSCO) trades at $30.24, down 0.62% on the day, with a bearish technical signal and mixed earnings history. Recent quarters show two misses, but Q2 2026 expectations are set at $0.85 EPS. The company maintains stable revenue growth, reaching $15.52B in 2025, with a net income margin of 6.91% and a strong ROE of 45.5%. A recent partnership with Instacart aims to expand delivery services for rural customers.
The stock presents a value opportunity with a P/E of 14.9 below industry averages, supported by a 48% analyst buy rating and a $40 consensus price target implying significant upside. Risks include recent earnings volatility, consumer spending pressures, and competitive retail dynamics. The dividend yield of approximately 3.2% adds income appeal for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Tractor Supply Co
Tractor Supply is the largest operator of retail farm and ranch stores in the United States. The company targets recreational farmers and ranchers and has little exposure to commercial and industrial farm operations. Currently, the company operates 2,016 of its namesake banners in 49 states and 178 Petsense stores. Stores are typically located in towns outside of urban areas and in rural communities. In fiscal 2021, revenue consisted primarily of livestock and pet (47%), hardware, tools, and truck (21%), and seasonal gift and toy (21%).
Read more on TSCO →
